

## Biography



DOB: February 8, 1953  
New York

May, 1975: B.A., Chemistry, Syracuse University  
Advisor: [Professor Ei-ichi Negishi](#) (synthesis)

1975-1979: Ph.D., Chemistry, Massachusetts Institute of Technology  
Advisor: [Dr. W. H. Rastetter](#) (Epidithiapiperazinedione syntheses)

1979-1980: Postdoc, Harvard University  
Advisor: [Professor Y. Kishi](#) (Total synthesis of erythromycin A)

### Independent Career:

1980-1985: Assistant Professor, Colorado State University

1985-1988: Associate Professor, Colorado State University

1988-2002: Full Professor, Colorado State University

1994-present: Member, Editorial Board "*Chemistry and Biology*"

2002-present: University Distinguished Professor, Colorado State University

2012-present: Director for the Colorado Center of Drug Discovery (C2D2)

Current Group: 2 postdocs; 6 graduate students

Alumni: 78 former postdocs and 56 graduate students; 25 in academia

### Primary Research Areas:


- Unnatural Amino Acid Synthesis
- Secondary Metabolite Total Synthesis
- Biosynthesis

## Awards


- Ernest Guenther Award in the Chemistry of Natural Products, American Chemical Society (2011)
- Multiple Myeloma Research Foundation Senior Award (2009-2011)
- University Distinguished Professor, Colorado State University (2002)
- Arthur C. Cope Scholar Award, American Chemical Society (2002)
- Japanese Society for the Promotion of Science (JSPS) Fellowship (1999)
- Merck & Co. Academic Development Award (1991-93)
- Fellow of the Alfred P. Sloan Foundation (1986-88)
- Eli Lilly Young Investigator Grantee (1986-88)
- NIH Research Career Development Awardee (1984-89)

## Research Impact (from Web of Science)

Published Items in Each Year 311 total publications




Citations in Each Year Times Cited: 4138



### Top 5 cited papers:

1. Biosynthesis of prenylated alkaloids derived from tryptophan. *Top. Curr. Chem.* **2000**, 209, 97–174
2. Concise, asymmetric total synthesis of spirotryprostatin A. *Org. Lett.*, **2003**, 5 (17), 3135–3137
3. Asymmetric synthesis of 2,6-diaminopimelic acids. *J. Org. Chem.*, **1992**, 57 (24), 6519–6527
4. A concise formal total synthesis of TMC-95A/B proteasome inhibitors *Org. Lett.*, **2003**, 5 (2), 197–200
5. Asymmetric total synthesis of (+) and (–) spirotryprostatin B *Tetrahedron*, **2002**, 58, 6311–6322


Electrophilic Glycinates (diphenyloxazinones)



RM	Reaction Condition	Yield	Amino Acid	% ee
	ZnCl <sub>2</sub> (1.2 eq), THF, rt, 1hr	71%	D-β-ethylaspartate**	96.6
	ZnCl <sub>2</sub> (1.2 eq), THF, rt, 1hr	54 %	L-homophenylalanine	96.9
	ZnCl <sub>2</sub> (2 eq), THF, rt, 3 days	68%	L-norvaline, L-allylglycine	98.3
MeZnCl	THF, rt, 1 hr	46%	L-alanine	96.8
Me <sub>2</sub> CuCNLi <sub>2</sub>	THF, -78 °C, 0.5 hr	28%		
Bu <sub>2</sub> CuCNLi <sub>2</sub>	THF, -78 °C, 0.5 hr	48%	L-norleucine	99.5

RM	Reaction Condition	% Yield (UAA)	% ee
	Et <sub>2</sub> O/THF, -78 °C, 1hr	52	82
	Et <sub>2</sub> O/THF, -78 °C, 1.5 hr	29	94
	ZnCl <sub>2</sub> , THF, 25 °C, 4.5hr	62	91
	ZnCl <sub>2</sub> , THF, 25 °C, 5.5hr 4 Å M.S.	26	90
	ZnCl <sub>2</sub> , MeCN, 25 °C, 4hr 4 Å M.S.	73	93

### $\alpha$ -Monosubstituted $\alpha$ -Amino Acids




$\text{R}_1\text{X}$	Base (eq.)	% yield
$\text{H}_2\text{C}=\text{CHCH}_2\text{I}$	$\text{LiN}(\text{SiMe}_3)_2$ (1.2)	82
$\text{CH}_3\text{I}$	$\text{NaN}(\text{SiMe}_3)_2$ (1.1)	88
$\text{PhCH}_2\text{Br}$	$\text{NaN}(\text{SiMe}_3)_2$ (1.2)	77
$\text{Me}_2\text{C}=\text{CHCH}_2\text{Br}$	$\text{NaN}(\text{SiMe}_3)_2$ (1.1)	84
$\text{BrCH}_2\text{CO}_2\text{Et}$	$\text{NaN}(\text{SiMe}_3)_2$ (1.1)	64*
$n\text{-C}_3\text{H}_7\text{I}$	$\text{NaN}(\text{SiMe}_3)_2$ (1.5)	76

#### Important Notes:

- The base should be added to a stirring solution of the oxazinone and the electrophile at  $-80^\circ\text{C}$  in order to prevent double alkylation (This is more pertinent for unactivated electrophiles).  
- It was noted that the addition of HMPA greatly increased the yields, likely through the prevention of aggregate formation.
- KHMDS appears to be too reactive and tends to generate dialkylated products.  
- LDA, *n*-BuLi, *t*-BuLi, and NaH showed no "satisfactory" alkylation

### $\alpha,\alpha$ -Disubstituted Amino Acids




$\text{R}_1$	$\text{R}_2\text{X}$	$\text{KN}(\text{SiMe}_3)_2$ equiv.	% yield
Me	$\text{PhCH}_2\text{Br}$	2	84
<i>n</i> - $\text{C}_3\text{H}_7$	$\text{PhCH}_2\text{Br}$	2	0
<i>n</i> - $\text{C}_3\text{H}_7$	$\text{PhCH}_2\text{Br}$	5	85
allyl	$\text{PhCH}_2\text{Br}$	3	84


#### Important Notes:

- The same protocol for monosubstituted amino acids had to be used however KHMDS was the only base that proved successful under the reaction conditions.  
- HMPA as an additive led to lower yields (It is presumed that the employment of HMPA for the more reactive potassium enolates only promotes decomposition).


### Mechanistic Rationale




Synthesis of  $\alpha$ -Hydroxy- $\beta$ -amino Acids




**Total Synthesis of (±) and (+) Bicyclomycin:**







Total Synthesis of (-)-Brevianamide B



**Total Synthesis of (±)-Aspirochlorine**




**Total Synthesis of (+)-Paraherquamide B**







**Total Synthesis of (+),(-)-Spirotryprostatin B**




**Total Synthesis of Spirotryprostatin A**




Total Synthesis of (-)-Jorumycin, (-)-Renieramycin G



Total Synthesis of (-)-Jorumycin, (-)-Renieramycin G (Continued)





**Total Synthesis of Stephacidins A, B and Notoamide B**




Approaches to construct the bicyclo[2.2.2]diazaoctane nucleus


Williams






Liebscher




Myers



Baran




Total Synthesis of Ecteinascidin 743 (E.J. Corey)




## Williams Formal Synthesis of Ecteinascidin 743

Fukuyama's Key Ring Forming Reactions



Williams Formal Synthesis



**Total Synthesis of (+)-FR66979 and (+)-FR900482**

